Skip to main content
Neurology: Clinical Practice logoLink to Neurology: Clinical Practice
letter
. 2015 Oct;5(5):366–368. doi: 10.1212/01.CPJ.0000472923.37443.61

Dystonia

Five new things

Stella Marousi 1, Richard Grünewald 1
PMCID: PMC5762016  PMID: 29443166

We read with interest the article “Dystonia: Five new things” by Berman and Jinnah.1 The authors describe evidence that dystonia is a complex network disorder arising from the dysfunction of one or more parts of the brain, including the basal ganglia, thalami, cortex, cerebellum, and pontine and dentate nuclei. We would like to stress that muscle spindles and their distorted proprioceptive feedback to central processing structures also form a crucial part of the pathophysiologic network described above.2

We have demonstrated that idiopathic focal dystonias are underpinned by abnormalities in genetically determined physical properties of muscle spindles, which produce aberrant fatigue-induced proprioceptive signals.3 This genetic predisposition possibly interacts with other related genetic changes (i.e., TOR1A, THAP1) that have only partial penetrance in order to produce the dystonic phenotype.4 Moreover, it has previously been shown that, apart from its peripheral effects, botulinum toxin may also work by inducing central “cortical molding” through modulation of the afferent muscle spindle inputs.2,5 Thus, the primary abnormality in idiopathic focal dystonia may not lie exclusively in the brain. Although science has thrown some light onto the pathophysiology of dystonia, the scene is much easier to interpret if the key player is acknowledged.

Disclosures:

The authors report no disclosures.

References

  • 1.Berman BD, Jinnah HA. Dystonia: five new things. Neurol Clin Pract. 2015;5:232–240. doi: 10.1212/CPJ.0000000000000128. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 2.Kanovsky P, Rosales RL. Debunking the pathophysiological puzzle of dystonia—with special reference to botulinum toxin therapy. Parkinsonism Relat Disord. 2011;17:S11–S14. doi: 10.1016/j.parkreldis.2011.06.018. [DOI] [PubMed] [Google Scholar]
  • 3.Frima N, Rome SM, Gruüewald RA. The effect of fatigue on abnormal vibration induced illusion of movement in idiopathic focal dystonia. J Neurol Neurosurg Psychiatry. 2003;74:1154–1156. doi: 10.1136/jnnp.74.8.1154. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 4.Frima N, Nasir J, Gruüewald RA. Abnormal vibration-induced illusion of movement in idiopathic focal dystonia: an endophenotypic marker? Mov Disord. 2008;23:373–377. doi: 10.1002/mds.21838. [DOI] [PubMed] [Google Scholar]
  • 5.Walsh R, Hutchinson M. Molding the sensory cortex: spatial acuity improves after botulinum toxin treatment for cervical dystonia. Mov Disord. 2007;22:2443–2446. doi: 10.1002/mds.21759. [DOI] [PubMed] [Google Scholar]
Neurol Clin Pract. 2015 Oct;5(5):366–368.

Authors Respond:


Brian D. Berman, MD, MS, H.A. Jinnah, MD, PhD: We would like to thank Marousi and Grünewald for responding to our article1 and for pointing out that the entire network involved in the pathogenesis of the many different types of dystonia is not yet fully delineated. We are aware of the evidence that peripheral mechanisms, including abnormal proprioceptive feedback from muscle spindles, may contribute to dystonia. It is interesting to note that this sensory information has direct connections to the cerebellum, so it is not hard to imagine that faulty source information from spindle afferents and faulty processing within the cerebellum could both cause dystonia. More research is needed to determine whether peripheral mechanisms are causal or consequential, whether they play a central role in all forms of dystonia or only some subtypes, and how they might be exploited to treat dystonia.

University of Colorado Denver (BDB), Aurora, CO; and Emory University (HAJ), Atlanta, GA.

Disclosures: B.D. Berman serves on the medical advisory boards for the Benign Essential Blepharospasm Research Foundation and the National Spasmodic Torticollis Association; has received funding for travel to conferences from Parkinson Study Group, American Neurological Association, Movement Disorder Society, Dystonia Medical Research Foundation, and Benign Essential Blepharospasm Research Foundation; serves on the editorial board of Journal of Neurology and Neurophysiology; and receives research support from the NIH, Dystonia Coalition, Dystonia Medical Research Foundation, Colorado Translational Research Imaging Center, University of Colorado Center for Neuroscience, The Dana Foundation, and the Benign Essential Blepharospasm Research Foundation. H.A. Jinnah serves on the scientific advisory boards for Cure Dystonia Now, the Dystonia Medical Research Foundation, Tyler's Hope for a Dystonia Cure, the Lesch-Nyhan Syndrome Children's Research Foundation, and Lesch-Nyhan Action France; has received funding for travel or speaker honoraria from Bachmann-Strauss Dystonia & Parkinson's Foundation, Dystonia Medical Research Foundation, National Spasmodic Torticollis Association, Tyler's Hope, and Cure Dystonia Now; serves as a consultant for Psyadon Pharmaceuticals and Medtronic, Inc.; provides botulinum toxin injections as a clinical service; has received research support from Psyadon Pharmaceuticals, Merz Pharmaceuticals, Ipsen Pharmaceuticals, NIH/National Institute of Neurological Disorders and Stroke, Emory Neurosciences Initiative, Atlanta Clinical and Translational Institute, Emory University Research Council, Bachmann-Strauss Dystonia & Parkinson's Foundation, Dystonia Medical Research Foundation, Lesch-Nyhan Syndrome Children's Research Foundation, Dystonia Coalition, Benign Essential Blepharospasm Research Foundation, and Cure Dystonia Now; and is principal investigator for the Dystonia Coalition, which receives the majority of its support through NIH grant NS065701 from the Office of Rare Diseases Research in the National Center for Advancing Translational Science and National Institute of Neurological Disorders and Stroke. The Dystonia Coalition also receives additional material or administrative support from industry sponsors (Allergan Inc., Ipsen Biopharm, Medtronic Inc., and Merz Pharmaceuticals) as well as private foundations (The American Dystonia Society, The Bachmann-Strauss Dystonia and Parkinson Foundation, BeatDystonia, the Benign Essential Blepharospasm Foundation, Dystonia Europe, Dystonia Ireland, the Dystonia Medical Research Foundation, The Dystonia Society, The Foundation for Dystonia Research, the National Spasmodic Dysphonia Association, and the National Spasmodic Torticollis Association).


Articles from Neurology: Clinical Practice are provided here courtesy of American Academy of Neurology

RESOURCES